IL6 and neoplasm: In a study performed using serum from patients participating in a phase II clinical trial assessing the tumor response in patients with advanced pancreatic cancer receiving gemcitabine and IV omega-3 rich lipid emulsion, Arshad et al. [104] showed that low IL-6-levels correlated with improved OS, with a median OS of 7 months vs. 3.5 months for patients with high IL-6 levels.